Table 2.

Prophylaxis details by surgery risk status.

Type of surgery	Procedural characteristics	Antifibrinolytic therapy only	Antifibrinolytic therapy + DDAVP	Antifibrinolytic therapy + VWF concentrate	DDAVP only	None
Major -Body cavity was entered -Mesenchymal barrier entered (pleura, peritoneum, or dura) -Fascial plane was opened -Organ was removed -Normal anatomy was operatively altered (circumcision, septoplasty, tonsillectomy, and adenoidectomy) -Interventions involving joints -Third molar extractions -Surgery where severe hemorrhage is possible	Number of events	44	12	3	0	0
	Antifibrinolytic frequency	Twice daily (1); 3 times daily (41); 4 times daily (1)	Three times daily	Three times daily	NA	NA
	Antifibrinolytic duration (d)	8 (5-10)	7 (7-10)	10 (7.5-10)	NA	NA
	DDAVP or VWF concentrate dose (n), route of administration,and dosage	NA	Dose (n): 1 Route: IN (10), i.v. (2) Dose: weight-based (IN) 0.3 mcg/kg i.v.	Dose (n): median 1, range 1-3 Route: i.v. Dose: 40-50 units/kg	NA	NA
	DDAVP or VWF concentrate timing	NA	Preprocedural (n = 12)	Preprocedural (n = 2) Preprocedural, days 1 and 3 (n = 1)	NA	NA
	Bleeding events	0	1 major: hemoglobin drop >2 g, hospital admission	0	0	0
	Bleeding event treatment	NA	Antifibrinolytics, DDAVP	NA	NA	NA
Minor Invasive operative procedure in which only skin, mucous membranes, or superficial connective tissue was manipulated. Includes scopes, IUD insertion, therapeutic intramuscular injections, tympanostomy, and bone marrow biopsy.	Number of events	56	2	4	1	3
	Antifibrinolytic frequency	Daily (6); twice daily (6); 3 times daily (40); 4 times daily (2); unknown (2)	Three times daily (1); 4 times daily (1)	Three times daily (4)	NA	NA
	Antifibrinolytic duration (d)	2 (2-3)	3.5 (2.75-4.25)	4 (2.75-5)	NA	NA
	DDAVP or VWF concentrate dose (n), route of administration, and dosage	NA	Dose: 1 Route: IN (2) Dose: weight-based (IN)	Dose: 1 Route: i.v. (4) Dose: 40 (37.1-42.5) units/kg	Dose: 1 Route: IN Dose: weight-based	NA
	DDAVP or VWF concentrate timing	NA	Preprocedural (n = 2)	Preprocedural (n = 4)	Preprocedural	NA
	Bleeding events	4 - 2 CRNM - 2 calls to the nursing team	1 1 CRNM: ER visit for surgical site bleeding	1 1 CRNM: surgical site bleeding requiring medication	0	1 1 CRNM: surgical site bleeding, call to nurses, ER visit for bleeding
	Bleeding event treatment	Antifibrinolytics (2)	Antifibrinolytics	VWF concentrate	NA	Antifibrinolytics
Dental Nonthird molar extractions, crowns, and fillings	Number of events	28	3	5	0	0
	Antifibrinolytic frequency	Daily (2); twice daily (3); 3 times daily (23)	Three times daily (3)	Three times daily (5)
	Antifibrinolytic duration (d)	5 (3-10)	10 (8.5-10)	3 (2-7)
	DDAVP or VWF concentrate dose (n), route of administration, and dosage	NA	Dose (n): 1 Route: IN (2), i.v. (1) Dose: weight-based (IN) 0.3 mcg/kg (i.v.)	Dose (n): 1 Route: i.v. (5) Dose: 50 units/kg (range, 30-50)
	DDAVP or VWF concentrate timing	NA	Preoperative (3)	Preoperative (5)
	Bleeding events	0	0	0
	Bleeding event treatment	NA	NA	NA

Data are reported as median with IQR, unless otherwise stated.

CRNM, clinically relevant nonmajor bleeding; DDAVP, desmopressin; Dose (n), number of doses; ER, emergency room; IN, intranasal; IUD, intrauterine device; i.v., intravenous; NA, not applicable; VWF, von Willebrand factor.